Akso Health Group (AHG) Stock Analysis
Verdict: AVOID
Extreme cash depletion to $171k and continuous share dilution render AHG fundamentally unviable despite speculative daily price pumps.
Investment score: 14/100
Analysis as of
Is Akso Health Group stock worth reviewing? The TradeMates thesis
Akso Health Group presents extreme solvency and dilution risks, with liquid cash dropping to $170.5k against an annual operating loss of -$4.0M.
7-factor investment score
- Valuation: 10/100 (weight 20%)
- Financial Health: 5/100 (weight 15%)
- Technical Momentum: 30/100 (weight 15%)
- Earnings Quality: 10/100 (weight 15%)
- Insider Sentiment: 20/100 (weight 10%)
- Analyst Consensus: 20/100 (weight 10%)
- Risk-Adjusted Return: 10/100 (weight 15%)
Akso Health Group opportunities and risks
What speaks for AHG
- Short-term technical momentum spikes created by low float dynamics
What speaks against AHG
- Immediate cash depletion and runway exhaustion
Peers and competitors
- 1345.HK
- 000705.SZ
- 9885.HK
- 301126.SZ
- 2656.HK
- 1931.HK
- 2289.HK
- 6833.HK
Frequently asked questions about Akso Health Group (AHG)
Is AHG stock a good investment?
The TradeMates model rates Akso Health Group as AVOID with an investment score of 14/100. Akso Health Group presents extreme solvency and dilution risks, with liquid cash dropping to $170.5k against an annual operating loss of -$4.0M. This is algorithmic model output, not personal investment advice.
Is AHG stock a buy?
The TradeMates model verdict for AHG is AVOID with an investment score of 14/100. Treat this as a model signal to review, not a personal buy recommendation.